Rapid Response to Trastuzumab Emtansine in a Patient with HER2-Driven Lung Cancer Daniela Weiler, MD, Joachim Diebold, MD, Klaus Strobel, MD, Stefan.

Slides:

Advertisements

Similar presentations

Frances A Shepherd, MD, Rafael Rosell, MD Journal of Thoracic Oncology

Advertisements

Naomi Fujioka, MD, Christopher A. French, MD, Michael J

Next Generation Sequencing Uncovers Potential Genetic Driver Mutations of Malignant Pulmonary Granular Cell Tumor Song Xu, Qingchun Zhao, Sen Wei, Yi.

Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD Journal of Thoracic Oncology

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

Response to Crizotinib/Erlotinib Combination in a Patient with a Primary EGFR-Mutant Adenocarcinoma and a Primary c-met–Amplified Adenocarcinoma of the.

ALK FISH and IHC: You Cannot Have One without the Other

Transformation to Sarcomatoid Carcinoma in ALK-Rearranged Adenocarcinoma, Which Developed Acquired Resistance to Crizotinib and Received Subsequent Chemotherapies

Durable Response to Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem Kinase Domain Duplication

Erlotinib Response in an NSCLC Patient with a Novel Compound G719D+L861R Mutation in EGFR Eamon M. Berge, MD, Dara L. Aisner, MD, PhD, Robert C. Doebele,

MET-Mutated NSCLC with Major Response to Crizotinib

Bob T. Li, M. B. B. S. , MPH, Dara S. Ross, MD, Dara L

KRAS Mutation Analysis Helps to Differentiate Between Pulmonary Metastasis from Colon Adenocarcinoma In Situ and Primary Lung Adenocarcinoma Taylor M.

NA Journal of Thoracic Oncology

Electronic Updates for JTO Readers

How I Do It—Optimal Methodology for Multidirectional Analysis of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Samples Takahiro Nakajima,

Primary Pulmonary NUT Midline Carcinoma: Clinical, Radiographic, and Pathologic Characterizations Lynette M. Sholl, MD, Mizuki Nishino, MD, Saraswati.

Numb Chin Syndrome: An Ominous Sign of Lung Cancer

An Unusual Presentation of Malignant Pleural Mesothelioma

Complete Radiological Response of Metastatic Anaplastic Lymphoma Kinase-Positive Signet Ring Lung Adenocarcinoma to Systemic Chemotherapy Grzegorz Korpanty,

A Case of Squamous Cell Carcinoma Harboring an EML4-ALK Rearrangement that Was Unsuccessfully Treated with the ALK Inhibitor Alectinib Akihiro Tamiya,

Combined Use of ALK Immunohistochemistry and FISH for Optimal Detection of ALK- Rearranged Lung Adenocarcinomas Lynette M. Sholl, MD, Stanislawa Weremowicz,

Surgical Treatment of a Giant Symptomatic Cardiac Lipoma

EGFR Exon 19 Insertions Show Good Response to Gefitinib, but Short Time to Progression in Japanese Patients Jangchul Park, MD, Chiaki Kondo, MD, Junichi.

A Severe Photosensitivity Dermatitis Caused by Crizotinib

A Case of Invasive Mucinous Pulmonary Adenocarcinoma with a CD74-NRG1 Fusion Protein Targeted with Afatinib Parneet K. Cheema, MD, MBiotech, FRCPC Journal.

Multiple Pulmonary Chondroid Hamartoma

ALK Rearrangement Detected in a Focus of Pulmonary Atypical Adenomatous Hyperplasia Filippo Lococo, MD, Alessandra Bisagni, MD, Maria Cecilia Mengoli,

Effective Treatment with Icotinib in Primary Adenoid Cystic Carcinoma of the Lung with Liver Metastasis Zhengbo Song, MD, Wei Wu, MD, Yiping Zhang, MD

A New KIT Gene Mutation in Thymic Cancer and a Promising Response to Imatinib Sung Hee Lim, MD, Ji-Yun Lee, MD, Jong-Mu Sun, MD, PhD, Kyoung-Mee Kim,

Liping Zhang, MD, Hui Yu, MD, PhD, Andrzej Badzio, MD, PhD, Theresa A

Metastasectomy in a lung graft using high-flow venovenous extracorporeal lung support in a patient after single lung transplantation Bassam Redwan, MD,

Transformation to SCLC after Treatment with the ALK Inhibitor Alectinib Shiro Fujita, MD, PhD, Katsuhiro Masago, MD, PhD, Nobuyuki Katakami, MD, PhD,

A Lung Cancer Responding to Hormonal Therapy

Aya Fukuizumi, MD Journal of Thoracic Oncology

A Comprehensive Analysis of p16 Expression, Gene Status, and Promoter Hypermethylation In Surgically Resected Non-small Cell Lung Carcinomas William.

Elderly Former Smoker with HRAS Mutant Non–Small-Cell Lung Cancer

Response to Crizotinib Observed in Lung Adenocarcinoma with MET Copy Number Gain but without a High-Level MET/CEP7 Ratio, MET Overexpression, or Exon.

Erratum Journal of Thoracic Oncology

A Patient With BRAF V600E Lung Adenocarcinoma Responding to Vemurafenib Oliver Gautschi, MD, Chantal Pauli, MD, Klaus Strobel, MD, Astrid Hirschmann,

Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response

Four-Year Complete Remission in a Patient with Metastatic Epidermal Growth Factor Receptor–Mutated Lung Cancer Treated with Two Cycles of Erlotinib Brendan.

Arnaud Uguen, MD, PhD Journal of Thoracic Oncology

Non–Small-Cell Lung Cancer with HER2 Exon 20 Mutation: Regression with Dual HER2 Inhibition and Anti-VEGF Combination Treatment Gerald S. Falchook, MD,

High MET Receptor Expression But Not Gene Amplification in ALK 2p23 Rearrangement Positive Non–Small-Cell Lung Cancer Yan Feng, MD, Eugen C. Minca, MD,

Elizabeth Cathcart-Rake, MD, Ariel Lopez-Chavez, MD, MS

Positron Emission Tomography 18F-Fluorodeoxyglucose Uptake and Prognosis in Patients with Surgically Treated, Stage I Non-small Cell Lung Cancer: A Systematic.

Amplification of MET in a Patient with Malignant Pleural Mesothelioma

A Rare Central Thoracic Tumor

Aglaya G. Iyevleva, MD, PhD Journal of Thoracic Oncology

Osimertinib for Epidermal Growth Factor Receptor Mutation–Positive Lung Adenocarcinoma That Transformed to T790M-Positive Squamous Cell Carcinoma Naoyuki.

Mirror Mirror on the Wall, Who Is the Fairest of Them All

EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer Allison Ackerman, MD, Michael A. Goldstein,

EGFR Mutation and Brain Metastasis in Pulmonary Adenocarcinomas

Nivolumab-Induced Granulomatous Inflammation of the Pleura

Lung Adenocarcinoma with Concurrent Exon 19 EGFR Mutation and ALK Rearrangement Responding to Erlotinib Sanjay Popat, MRCP, PhD, Alexandra Vieira de.

Histological Subtypes of Lung Adenocarcinoma Have Differential 18F- Fluorodeoxyglucose Uptakes on the Positron Emission Tomography/Computed Tomography.

A Rare Subglottic Capillary Hemangioma

A Rare Case of Endobronchial Amelanotic Melanoma

Beware of the “Bronchocele,” Particularly in Patients with a History or Risk Factors for a Mucinous Carcinoma: A Response to the Article “Resection of.

Concomitant Epidermal Growth Factor Receptor Mutation and EML4-ALK Fusion in a Patient with Multifocal Lung Adenocarcinomas Jun Fan, MD Journal of Thoracic.

Marianna Koczywas, MD, Mihaela C. Cristea, MD

European Lung Cancer Conference (ELCC) 2016 Organisation

Metastatic Lung Cancer to the Pancreas

Successful AZD9291 Therapy Based on Circulating T790M

IASLC 6th Latin American Conference on Lung Cancer

Super Scan Using Positron Emission Tomography in Lung Cancer Patients

Waxing and Waning of MET Amplification in EGFR-Mutated NSCLC in Response to the Presence and Absence of Erlotinib Selection Pressure Joel P. Womack,

Ana Luque, MD, Edurne Arriola, MD, PhD Journal of Thoracic Oncology

Presentation transcript:

Rapid Response to Trastuzumab Emtansine in a Patient with HER2-Driven Lung Cancer Daniela Weiler, MD, Joachim Diebold, MD, Klaus Strobel, MD, Stefan Aebi, MD, Oliver Gautschi, MD Journal of Thoracic Oncology Volume 10, Issue 4, Pages e16-e17 (April 2015) DOI: 10.1097/JTO.0000000000000424 Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Histology with adenocarcinoma (hematoxylin and eosin staining) (A); immunohistochemistry with TTF1 expression (B); Sanger read with human epidermal growth factor receptor 2 (HER2) p.A775_G776insYVMA (C); and simultaneous HER2 immunohistochemistry and dual chromogenic in situ hybridization with HER2 overexpression (score 2+, brown color) and HER2 amplification (2.3 ratio of black HER2 and red CEP17 signals) (D). Journal of Thoracic Oncology 2015 10, e16-e17DOI: (10.1097/JTO.0000000000000424) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 18Fluorodeoxyglucose positron emission tomography and computer tomography scans 1 week before the start of trastuzumab emtansine (A, B, C); at the end of cycle 1 (D, E, F); and at the end of cycle 2 (G, H, I), showing rapid metabolic and morphologic response. Journal of Thoracic Oncology 2015 10, e16-e17DOI: (10.1097/JTO.0000000000000424) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions